Characteristics of the 25 patients experiencing a thrombotic event during the study period
. | . | Symptomatic . | . | Site of arterial thrombosis . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
. | Total . | Deep vein thrombosis . | Pulmonary embolism . | Femoral . | Cerebral . | Coronary . | Mesenteric . | ||||
| No. patients | 25 | 7 | 7 | 6 | 2 | 2 | 1 | ||||
| Patients with disseminated intravascular coagulation | 2 | 0 | 1 | 1 | 0 | 0 | 0 | ||||
| Event during the first day of lepirudin therapy | 3 | 1 | 0 | 0 | 1 | 1 | 0 | ||||
| Event during lepirudin/vitamin K antagonist overlap | 16 | 7 | 5 | 4 | 0 | 0 | 0 | ||||
| Death during lepirudin therapy | 6 | 0 | 2 | 1 | 1 | 1 | 1 | ||||
. | . | Symptomatic . | . | Site of arterial thrombosis . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
. | Total . | Deep vein thrombosis . | Pulmonary embolism . | Femoral . | Cerebral . | Coronary . | Mesenteric . | ||||
| No. patients | 25 | 7 | 7 | 6 | 2 | 2 | 1 | ||||
| Patients with disseminated intravascular coagulation | 2 | 0 | 1 | 1 | 0 | 0 | 0 | ||||
| Event during the first day of lepirudin therapy | 3 | 1 | 0 | 0 | 1 | 1 | 0 | ||||
| Event during lepirudin/vitamin K antagonist overlap | 16 | 7 | 5 | 4 | 0 | 0 | 0 | ||||
| Death during lepirudin therapy | 6 | 0 | 2 | 1 | 1 | 1 | 1 | ||||
Seven patients experienced an extension or a recurrence of a previous thrombotic event, as follows: extension of lower limb deep-vein thrombosis (3 patients), extension of lower limb arterial thrombosis (2 patients), pulmonary embolism recurrence (1 patient), myocardial reinfarction (1 patient)